Olivier GLEHEN, MD, PhD

Nov 6, 2026 · @Olivier Glehen



Professor of Surgery, Université Claude Bernard Lyon 1 – Head of the Peritoneal Surface Malignancy Programme, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, France

Department of Digestive and Oncological Surgery, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet, 69495 Pierre-Bénite, France · olivier.glehen@chu-lyon.fr

Profile

Surgical oncologist dedicated to the multidisciplinary management of primary and secondary peritoneal surface malignancies of digestive and gynaecological origin. I lead one of the highest-volume programs worldwide (more than 4,000 cytoreductive surgeries with HIPEC, and a large PIPAC experience), coordinate the French national network for rare peritoneal tumours RENAPE, and direct the INSERM-labelled CICLY research team. My work focuses on generating high-level evidence for locoregional treatments of peritoneal metastases and on the international standardization of peritoneal surgery, through PSOGI, ISSPP and ESGO consensus programs.

Current positions

Since	Position
2006	Full Professor of Surgery (PU-PH, exceptional class since 2024), Université Claude Bernard Lyon 1; Department of Digestive and Oncological Surgery, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon (HCL)
2020	Director, CICLY research team, Université Lyon 1 (INSERM labelling obtained, effective 2027)
2018	Coordinator, French National Network for Rare Peritoneal Tumours RENAPE (INCa-labelled, renewed 2025) and its BIG-RENAPE clinical-biological database
2020	Head, ESGO-accredited centre for ovarian cancer surgery, Centre Hospitalier Lyon Sud

Since	Position
	(ESGO Centre of Excellence, 2026)
2020	President, College of Visceral and Digestive Surgery of Lyon; elected member of the HCL Research Bureau (since 2022)
2026	Associate Editor, European Journal of Surgical Oncology

Previous positions

Years	Position
2013–2020	Head, Department of General, Oncological and Endocrine Surgery, Centre Hospitalier Lyon Sud, HCL
2005–2020	Director, research team "Peritoneal Carcinomatosis", EMR 3738, Université Lyon 1
2003–2006	Associate Professor of General Surgery, Centre Hospitalier Lyon Sud, HCL
2002–2003	Research Fellow in Surgical Oncology, Washington Cancer Institute (Prof. P.H. Sugarbaker), Washington DC, USA
1999–2002	Assistant Professor of General Surgery (Chef de Clinique), Faculty Lyon Sud, HCL

Education and qualifications

Year	Degree
2022	University diploma in Health Management and Leadership (Lyon–Ottawa–Montréal)
2005	Habilitation to Supervise Research (HDR), Université Lyon 1
2004	PhD, Université Lyon 1: "Peritoneal carcinomatosis: from animal models to clinical practice"
2001	Board certification in Visceral and Digestive Surgery, Université Lyon 1
1999	MSc (DEA), "Adaptation and survival in extreme environments", Université Lyon 1
1998	Doctor of Medicine (MD), Université Lyon 1
1997	Board certification in General Surgery; MSc in Human Biology, Université Lyon 1
1993	Surgical residency, Hospices Civils de Lyon (Interne des Hôpitaux de Lyon)

Key contributions to peritoneal surface malignancy

- **Evidence for cytoreductive surgery and HIPEC.** Investigator and co-author of the academic phase 3 trials PRODIGE 7 (colorectal peritoneal metastases, Lancet Oncol 2021) and CHIPOR

(recurrent ovarian cancer, Lancet Oncol 2024); principal investigator of the national CYTO-CHIP study in gastric cancer (J Clin Oncol 2019; Br J Surg 2021).

- **International standardisation.** Co-lead of the PSOGI–ESGO–ISSPP Lyon consensus on peritonectomy procedures and the principles of cytoreductive surgery (three Br J Surg papers 2025; Lancet Oncol 2026), the 2022 PSOGI–ISSPP consensus on HIPEC regimens (Ann Surg Oncol 2023–2024) and the PSOGI–ISSPP–EURACAN guidelines for appendiceal tumours, pseudomyxoma peritonei and peritoneal mesothelioma.
- **PIPAC.** Contribution to the development of pressurised intraperitoneal aerosol chemotherapy, its rationale and indications (Lancet Oncol 2019) and its outcomes in a large prospective cohort (Ann Surg 2026); contributor to the ISSPP PIPAC database.
- **Organisation of care for rare peritoneal cancers.** Coordinator of RENAPE and BIG-RENAPE; national quality programmes, including the root-cause analysis of postoperative deaths after CRS-HIPEC in 5,562 patients (Ann Surg 2021), and national guidelines (TNCD).
- **Digital and translational tools.** Co-developer of the PROMISE software for Peritoneal Cancer Index assessment and of the CRS-Report platform for structured operative reporting (Eur J Surg Oncol 2026); supervision of translational research on intraperitoneal drug delivery and chemoresistance within CICLY.

International activities

- **ISSPP:** co-organiser of the first joint PSOGI–ISSPP congress (Lyon, 2024); ISSPP Peritoneum Prize (2024); invited faculty at the ISSPP international congresses (Los Angeles 2022; São Paulo 2026).
- **PSOGI:** member; organiser of the PSOGI International Workshops on Peritoneal Surface Malignancy (Lyon 2008 and 2024); faculty at 3–5 international workshops per year in Europe, Asia, the Middle East, Latin America and India.
- **ESSO:** mentor of the European School of Peritoneal Surface Malignancies (since 2014); faculty of the annual ESSO course on peritoneal carcinomatosis (since 2000).
- **Training:** more than 25 international surgeons and teams trained in CRS, HIPEC and PIPAC; more than 100 invited lectures.
- **Memberships:** PSOGI, ISSPP, European Surgical Association (since 2015), ESSO, ASPSM, EURACAN, FFCD, SFCO.

Editorial and expert roles

- Associate Editor, *European Journal of Surgical Oncology* (2026–2027); editorial boards of *Journal of Surgical Oncology*, *Journal of Peritoneum* and *Cancéro-Digest*.
- Reviewer for *Annals of Surgery*, *Annals of Surgical Oncology*, *British Journal of Surgery*, *European Journal of Cancer* and *International Journal of Hyperthermia*.
- Expert for the French National Authority for Health (HAS, HIPEC assessment 2021), the French National Cancer Institute (INCa) and the High Council for Nomenclature (since 2023).

Teaching and mentoring

Coordinator of the Inter-University Diploma on Peritoneal Carcinomatosis (since 2014). Supervisor of 8 completed and 7 ongoing PhD theses.

Awards

Antonin Poncet Prize (2001) · ASCO GI Merit Award (2004) · Chevalier des Palmes Académiques (2016) · INDEPSO "Rolling Stones" Award (2023) · ISSPP Peritoneum Prize (2024)

Publications

544 publications indexed in PubMed (192 since 2021) · Web of Science h-index 69 · SIGAPS score > 5,000 (October 2026).

Selected publications

1. Bhatt A, Stepanyan A, Al-Niaimi A, et al, **Glehen O**. Principles of cytoreductive surgery for primary and metastatic peritoneal malignancies – the PSOGI-ESGO-ISSPP Lyon consensus. *Lancet Oncol* 2026;27:e181-e194.
2. Bhatt A, Stepanyan A, Moran BJ, et al, **Glehen O**. Peritonectomy procedures for peritoneal surface malignancies: PSOGI-ESGO-ISSPP Lyon consensus. *Br J Surg* 2025;112:znaf112.
3. Classe JM, Meeus P, Hudry D, … **Glehen O**, et al. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2024;25:1551-1562.
4. Kepenekian V, Bhatt A, Péron J, et al, **Glehen O**. Advances in the management of peritoneal malignancies. *Nat Rev Clin Oncol* 2022;19:698-718.
5. Houlzé-Laroye C, **Glehen O**, Sgarbura O, et al. Half of postoperative deaths after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy could be preventable: a French root cause analysis on 5562 patients. *Ann Surg* 2021;274:797-804.
6. Quénet F, Elias D, Roca L, … **Glehen O**, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol* 2021;22:256-266.
7. Bonnot PE, Piessen G, Kepenekian V, et al, **Glehen O**. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. *J Clin Oncol* 2019;37:2028-2040.
8. Alyami M, Hübner M, Grass F, et al, **Glehen O**. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. *Lancet Oncol* 2019;20:e368-e377.
9. **Glehen O**, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. *Cancer* 2010;116:5608-5618.
10. **Glehen O**, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. *J Clin Oncol* 2004;22:3284-3292.